The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis

What Was Tested

This controlled clinical trial paper looks at Vasopressin and Desmopressin.

The relationship of functional bladder capacity as well as other variables to the responsiveness to desmopressin in children with monosymptomatic nocturnal enuresis was investigated.

Who Took Part

The abstract describes 95 children taking part.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

Evaluated predictors of response included patient age, gender, race, family history, number of baseline wet nights, urine osmolality parameters and maximum functional bladder capacity (as a percent of predicted bladder capacity based on the formula, patient age + 2 x 30 = cc).

How the Study Was Run

The design is described as double-blind, open-label and crossover.

Blinding on both sides kept the children and researchers unaware of who received Vasopressin.

Nothing was hidden in this open-label Vasopressin study: the children and staff both knew the treatment.

In the crossover set-up each of the children took both Vasopressin and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Deamino Arginine Vasopressin, Enuresis, Renal Agents and Urinary Bladder.

What This Means in Plain Language

The paper is a double-blind, open-label and crossover study of Vasopressin and Desmopressin in 95 children.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1996 (The Journal of urology), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.